{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.8"},{"groupId":"OG001","value":"59.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"146"}],"units":"Participants"}],"title":"H-score <200"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2"},{"groupId":"OG001","value":"40.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"title":"H-score >=200"}],"denoms":[{"counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"245"}],"units":"Participants"}],"description":"EGFR IHC H-score = weighted sum of % 1+ cells, twice % 2+ cells, and three times % 3+ cells. IHC H-score criteria assesses participants with a low EGFR expression defined by a H-score cutoff value of \\< 200 and participants with a high EGFR expression defined by a H-score of cutoff value of \\>=200.","groups":[{"description":"Necitumumab + Pemetrexed + Cisplatin\n\nNecitumumab: 800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V. infusion\n\nPemetrexed: 500 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles\n\nCisplatin: 75 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles","id":"OG000","title":"Necitumumab + Pemetrexed + Cisplatin"},{"description":"Pemetrexed + Cisplatin\n\nPemetrexed: 500 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles\n\nCisplatin: 75 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles","id":"OG001","title":"Pemetrexed + Cisplatin"}],"paramType":"NUMBER","populationDescription":"Translational research population included all participants who: (1) received at least one dose of study drug; (2) had a valid non-missing result for EGFR H-Score; and (3) were enrolled for more than 2 cycles prior to the decision to terminate enrollment","reportingStatus":"POSTED","timeFrame":"Baseline","title":"Percentage of Participants With EGFR Measured by IHC","type":"SECONDARY","unitOfMeasure":"percentage of participants"}